Index.php

Our attorneys have filed a mass tort lawsuit on behalf of patients who took the blood thinner Xarelto (rivaroxaban) and suffered significant bleeding events. Pharmaceutical organizations, such as the makers of Xarelto, possess a duty to ensure that their drugs are reasonably secure for use - and failure to accomplish so may possibly be grounds for compensation. Our lawyers are operating challenging to have those hurt by the drug the compensation they're entitled to.

Although bleeding is a widespread complication associated with anticoagulants, it has been alleged that Xarelto is more unsafe than traditional blood thinners due to the fact no antidote exists to reverse its blood-thinning effects. This implies that, inside the occasion of an emergency, individuals may possibly be at danger for irreversible bleeding issues, such as life-threatening internal and gastrointestinal hemorrhaging.

If you or even a loved 1 suffered a severe bleeding occasion following taking Xarelto, you might have legal recourse. For more data, make contact with us today to have your case reviewed, cost-free of charge.
Compensation Possibilities

xarelto-compensation-photoThe plaintiffs in these lawsuits are seeking compensation from Bayer and Janssen for past and future healthcare bills, lost wages, discomfort and suffering and, in circumstances of death, funeral expenses. In addition, they may be searching for punitive damages, which are usually awarded to punish the defendant and deter other organizations from acting similarly.
Why Are Lawsuits Becoming Filed?

Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several xarelto heart valve lawsuits alleging that the drug is unsafe and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Because of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding within the event of an emergency. Plaintiffs in the lawsuits allege significant and fatal injuries, such as cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.

In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:

The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and healthcare staff were not properly made aware of methods to stabilize and treat a Xarelto user inside the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to serious bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing dangerous clotting.

Visit this page for much more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set

The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.